2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to find out if D-Cycloserine (DCS), taken at the same time as a child gets cognitive behavioral therapy (CBT) can help children with pediatric obsessive-compulsive disorder.

Cognitive Behavior Therapy is a talking therapy that will teach children new skills to better cope with his/her OCD. CBT usually uses "exposure-based therapy". This means that the person with OCD slowly learns to deal with things they usually avoid. This is done by moving from less stressful situations to more challenging ones.

The investigators hope to enroll about 75 children ages 7-17 years old with OCD in this study at Massachusetts General Hospital (MGH). The National Institute of Mental Health (NIMH) is paying for this study to be done.

If your child qualifies for the study, the investigators will assign him or her by chance (like a coin toss) to either the DCS group or the placebo group. You and the study doctor cannot choose your child's study group. Your child will have an equal chance (1 in 2) of being assigned to the DCS group.

Your child will be asked to take one or two capsules of the study drug (either DCS or placebo, depending which study group they were assigned to) one hour before CBT visits 4-10. The study coordinator will give your child the study drug at the location of the CBT sessions. This is to make sure that your child takes the study drug one hour before his/her scheduled therapy session. We will ask you to record any bad side effect from the study drug that your child may have before each CBT session.

It will take your child about 34 weeks to complete the study. During this time, the investigators will ask you and your child to make a minimum of 17 trips to the study center. There may be up to 23 trips when including CBT Booster sessions.

This study uses a placebo. The placebo looks exactly like the DCS, but it contains no DCS. The investigators use placebos in research studies to learn if the the results are caused by the study drug or are due to other reasons. This is a double-blind study. A double-blind study is a study where both the doctor and the study participant do not know whether the study participant is being given DCS or placebo.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01404208
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	July 2011
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04934007` - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder	N/A
Recruiting	`NCT04071990` - Family Involvement in CBGT of OCD: a Randomized Controlled Trial	N/A
Completed	`NCT02541968` - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Recruiting	`NCT05391503` - Light Therapy for Obsessive-compulsive Disorder (OCD)	N/A
Recruiting	`NCT04539951` - Pragmatic Trial of Obsessive-compulsive Disorder	Phase 2
Completed	`NCT03416504` - Methods for Managing Intrusive Thoughts	N/A
Not yet recruiting	`NCT06029738` - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD	N/A
Recruiting	`NCT02844049` - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS	N/A
Completed	`NCT02911324` - Cannabinoid Medication for Adults With OCD	Phase 1/Phase 2
Terminated	`NCT02909660` - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder	N/A
Completed	`NCT02217995` - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients	N/A
Terminated	`NCT02234011` - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder	Phase 2
Withdrawn	`NCT01953042` - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders	N/A
Completed	`NCT02655926` - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder	N/A
Completed	`NCT04919785` - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder	N/A
Terminated	`NCT00758966` - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder	Phase 2
Completed	`NCT00742664` - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project	Phase 1/Phase 2
Completed	`NCT00523718` - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder	Phase 2
Completed	`NCT00074815` - Treatment of Obsessive Compulsive Disorder in Children	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.